Why is "Durvalumab" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-31 21:40:29
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Durvalumab entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-03-31 and was most recently seen on 2026-03-31.
Wikipedia Overview
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Tumor Boards and Prescribing Comfort With Durvalumab Plus BCG - Urology Times
-
Ivonescimab Beats Durvalumab in Phase III Biliary Tract Cancer Trial - The Clinical Trial Vanguard
-
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer - The ASCO Post
-
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study - Nature
-
EMERALD-3: Tremelimumab + Durvalumab Improves Clinical Outcomes When Combined With SOC in Unresectable HCC - ASCO Daily News
-
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com
-
Stage III NSCLC: Real-world durvalumab consolidation shows lower completion and more pneumonitis - Vera Health
-
First-Line Ivonescimab Plus Chemotherapy Meets OS End Point in Advanced Biliary Tract Cancer - onclive.com
-
FDA Approves Durvalumab and BCG for High-Risk NMIBC - Oncology Nursing News
-
Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC - CancerNetwork
-
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC - Targeted Oncology
-
Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC - Urology Times
-
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study - Nature
-
Durvalumab Plus BCG Shows No OS Detriment in BCG-Naive High-Risk NMIBC at 5 Years - onclive.com
-
Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC - The ASCO Post
-
Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC - CancerNetwork
-
Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC - Urology Times
-
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial - Nature
-
FDA approves durvalumab plus BCG for BCG-naïve, high-risk NMIBC - Urology Times
-
Durvalumab Plus BCG Shows Promise for High-Risk NMIBC - Oncology News Central
-
Proton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC - The ASCO Post
-
Durvalumab Offers New Path in Small Cell Lung Cancer Care - University of Miami
-
80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study - CancerNetwork
-
Extending the Academic NMIBC Care Model to Community Practice - Urology Times
-
Durvalumab Shows Similar Outcomes Across NSCLC PD-L1 Expression Groups - CancerNetwork
-
Perioperative Imfinzi (Durvalumab) Plus Chemotherapy FDA Approved for Muscle-Invasive Bladder Cancer - news.cancerconnect.com
-
Durvalumab/SBRT May Limit Tumor Progression in Early-Stage NSCLC - CancerNetwork
-
FDA Approves Durvalumab Plus BCG as First Immunotherapy Combo Regimen for High-Risk NMIBC - The American Journal of Managed Care
-
Ivonescimab Combination Improves Survival in Advanced Biliary Tract Cancer - Cure Today
-
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial - AstraZeneca
-
Durvalumab plus BCG shows consistent DFS benefit in older patients with high-risk NMIBC - Urology Times
-
FDA Approves Adding Durvalumab Immunotherapy To Prevent Stomach and Esophageal Cancer Recurrence - Memorial Sloan Kettering Cancer Center
-
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint - Yahoo Finance
-
ASCO GU 2026: PROs in Resected RCC: Active Monitoring versus Durvalumab and Tremelimumab in the RAMPART Trial - UroToday
-
Tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy in 1L non-squamous metastatic NSCLC with STK11, KEAP1 and/or KRAS mutations: Interim analysis of the phase 2b TRITON study - onclive.com
-
BEGONIA trial: durvalumab plus trastuzumab deruxtecan for HER2-low metastatic breast cancer - Bioengineer.org
-
HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial - Nature
-
PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC - medscape.com
-
Fabrice Barlesi, MD, PhD, on Resectable NSCLC: IPH5201 Plus Durvalumab and Platinum-Based Chemotherapy - The ASCO Post
-
Durvalumab Plus BCG Demonstrates Manageable Safety Profile in BCG-Naive High-Risk NMIBC - onclive.com
-
Adjuvant Durvalumab in Resected Early-Stage NSCLC - The ASCO Post
-
TOURMALINE: Safety and Efficacy of Durvalumab in Combination with Gemcitabine-Based Chemotherapy in Advanced Biliary Tract Cancer - emjreviews.com
-
RAMPART: Adjuvant Durvalumab Does Not Improve DFS vs Active Monitoring in Intermediate- and High-Risk RCC - ASCO Daily News
-
FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers - CancerNetwork
-
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma - Nature
-
FDA Approves Perioperative Durvalumab Plus FLOT for Gastric/GEJ Cancers - Oncology News Central
-
Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC - Targeted Oncology
-
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China - Business Wire
-
Durvalumab Monotherapy Misses DFS End Point in Adjuvant RCC - Targeted Oncology
-
Ivonescimab Combination Improves Overall Survival in First-Line Advanced Biliary Tract Cancer - Pharmacy Times
-
Could Proton Pump Inhibitors Affect Durvalumab Outcomes After Chemoradiotherapy in Stage III NSCLC? - Oncodaily
-
Reviewing the HIMALAYA Trial of Tremelimumab Plus Durvalumab in Unresectable HCC - CancerNetwork
-
Neo-CheckRay: iSBRT and Durvalumab in High-Risk ER+/HER2− Breast Cancer - Oncodaily
-
Imfinzi Combo Cuts Risk of Death by 25% in Advanced Biliary Tract Cancer - Cure Today
-
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer - The ASCO Post
-
NICE Backs First Immunotherapy for Resectable Gastric Cancer - medscape.com
-
Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers - AstraZeneca
-
Ceralasertib Plus Durvalumab Misses OS End Point in Previously Treated Advanced NSCLC - onclive.com
-
Safety and Efficacy of Synchronous Durvalumab with Hypofractionated Radiotherapy from the RAD-IO Study - Nicholas James - UroToday
-
Rintatolimod Plus Durvalumab Holds Post-Chemo Promise in Metastatic PDAC - Targeted Oncology
-
Unlocking Anti-Tumor Immunity With Durvalumab, Tremelimumab, and Enfortumab Vedotin - Pharmacy Times
-
FDA Approves Durvalumab Plus BCG for High-Risk Non–Muscle Invasive Bladder Cancer - Pharmacy Times
-
Durvalumab Plus Thoracic Radiotherapy Fails to Improve Survival in Extensive-Stage Small Cell Lung Cancer - Oncology News Central
-
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial - Nature
-
Behind the MATTERHORN Trial of Durvalumab/FLOT in Gastric/GEJ Cancer - CancerNetwork
-
NICE Backs Perioperative Immunotherapy for Bladder Cancer - medscape.com
-
A video summary of the TOPAZ-1 study PLSP: durvalumab and chemotherapy for advanced biliary tract cancer - Oncology Central
-
FDA Approves Perioperative Durvalumab for Resectable Gastric/GEJ Adenocarcinoma - onclive.com
-
FDA Approves Imfinzi Plus BCG for High-Risk Bladder Cancer - Cure Today
-
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer - Business Wire
-
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared To Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer In Single-Region Trial Conducted By Akeso In China - TradingView
-
Clinical Trial Hopes to Boost Survival Rates with Personalized Treatment for Extensive-Stage Small Cell Lung Cancer - Roswell Park Comprehensive Cancer Center
-
Patient-Reported Outcomes Support Durvalumab Consolidation Following Chemoradiotherapy in LS-SCLC - Pharmacy Times
-
Durvalumab’s recent failure to demonstrate improved overall survival highlights challenges in clinical development for head and neck cancer - Clinical Trials Arena
-
FDA Approves Durvalumab Plus FLOT in Early Stage Gastric/GEJ Cancers - Targeted Oncology
-
EMERALD-3 at ESMO GI 2026: Tremelimumab Plus Durvalumab With or Without Lenvatinib Plus TACE in Embolisation-Eligible HCC - Oncodaily
-
Cutaneous T-Cell Lymphoma: Use of Durvalumab Alone or With Lenalidomide Under Study in Phase II Trial - The ASCO Post
-
RAMPART at ASCO 2026: Durvalumab Monotherapy vs Active Monitoring in Resected Renal Cell Carcinoma - Oncodaily
-
The POTOMAC Trial and the Durvalumab-BCG Combination in High-Risk Non-Muscle-Invasive Bladder Cancer - Neal Shore - UroToday
-
LATIFY Trial: Ceralasertib Plus Durvalumab Fails to Improve Survival in Pre-Treated NSCLC - Oncodaily
-
ECOG-ACRIN 8192 Evaluates Preoperative Gemcitabine Plus Durvalumab in Cisplatin-Ineligible UTUC - Jeannie Hoffman-Censits - UroToday
-
TRITON Interim Analysis: Tremelimumab Plus Durvalumab And Chemotherapy Shows Early Response Signal In STK11/KEAP1/KRAS-Mutated NSCLC - Oncodaily
-
Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC - CancerNetwork
-
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer - MedPage Today
-
EMERALD-3 Durvalumab Combo Improves PFS in Embolization-Eligible HCC - CancerNetwork
-
FDA Approved Durvalumab Plus BCG for BCG-Naïve High-Risk NMIBC - Oncodaily
-
ADRIATIC clinical trial results suggest durvalumab may offer a new path in small cell lung cancer care - Medical Xpress
-
PATAPSCO Safety Data for BCG plus Durvalumab in High-Risk NMIBC - Mark Tyson - UroToday
-
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets - Yahoo Finance
-
Interpreting the POTOMAC Trial: Evaluating Durvalumab in BCG-Naïve NMIBC - Urology Times
-
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer - Business Wire
-
Durvalumab Plus BCG May Be New Treatment Option for BCG-Naïve, High-Risk NMIBC - Oncology Nurse Advisor
-
“Another Negative Study”: Phase 3 Failure for Lung Cancer Combo - Oncology News Central
-
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom
-
POTOMAC at ASCO 2026: Phase 3 Trial Reports 5-Year OS and PROs With Durvalumab Plus BCG in High-Risk NMIBC - Oncodaily
-
AEGEAN Trial: Durvalumab Reshapes the Tumor Microenvironment in Resectable NSCLC - Oncodaily
-
Perioperative durvalumab is not associated with HRQOL decline in MIBC - Urology Times
-
TOPAZ-1 Post Hoc Analysis: Durvalumab Plus GemCis in Advanced Biliary Tract Cancer - Oncodaily
-
GeparNuevo Long-Term Analysis: Durvalumab Improves Survival in Early Triple-Negative Breast Cancer - Oncodaily
-
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma - onclive.com
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.